Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma

BACKGROUND: Urothelial carcinoma (UC) is the second most common malignancy of the urinary system with high rate of recurrence, UC patients therefore needed to be treated with surgery followed by chemotherapy. Development of novel therapeutics with minimal side-effect is an urgent issue. Our previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Jou, Yeong-Chin, Lin, Guan-Ling, Lin, Hon-Yi, Huang, Wan-Hong, Chuang, Yu-Ming, Lin, Ru-Inn, Chen, Pie-Che, Wu, Shu-Fen, Shen, Cheng-Huang, Chan, Michael W. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054409/
https://www.ncbi.nlm.nih.gov/pubmed/33874979
http://dx.doi.org/10.1186/s12935-021-01925-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054409/
https://www.ncbi.nlm.nih.gov/pubmed/33874979
http://dx.doi.org/10.1186/s12935-021-01925-9

Ejemplares similares